MECP2 and neurodegenerative disease: These results indicate that MeCP2 could serve as an attractive target for conquering synaptic plasticity deficits and suggest that therapeutic strategies designed to remain or elevate MeCP2 expression may be beneficial to the treatment of age‐related cognitive decline in neurodegenerative diseases.